It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Polyols are effective against caries-causing streptococci but the effect on oropharynx-derived pyogenic streptococci is not well characterised. We aimed to study the effect of erythritol (ERY) and xylitol (XYL) against Streptococcus pyogenes isolated from peritonsillar abscesses (PTA). We used 31 clinical isolates and 5 throat culture collection strains. Inhibition of bacterial growth by polyols at 2.5%, 5% and 10% concentrations was studied and the results were scored. Amylase levels in PTA pus were compared to polyol effectivity scores (PES). Growth curves of four S. pyogenes isolates were analysed. Our study showed that XYL was more effective than ERY inhibiting 71–97% and 48–84% of isolates, respectively, depending of concentrations. 48% of clinical and all throat strains were inhibited by polyols in all concentrations (PES 3). PES was negative or zero in 26% of the isolates in the presence of ERY and in 19% of XYL. ERY enhanced the growth of S. pyogenes isolated from pus with high amylase levels. Polyols in all concentrations inhibited the growth in exponential phase. In conclusion, ERY and XYL are potent growth inhibitors of S. pyogenes isolated from PTA. Therefore, ERY and XYL may have potential in preventing PTA in the patients with frequent tonsillitis episodes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Tartu, Department of Microbiology, Institute of Biomedicine and Translational Medicine, Tartu, Estonia (GRID:grid.10939.32) (ISNI:0000 0001 0943 7661)
2 University of Tartu, Department of Oto-Rhino-Laryngology, Institute of Clinical Medicine, Tartu, Estonia (GRID:grid.10939.32) (ISNI:0000 0001 0943 7661); Ear-Nose-Throat Clinic, Tallinn, Estonia (GRID:grid.10939.32)
3 University of Tartu, Department of Microbiology, Institute of Biomedicine and Translational Medicine, Tartu, Estonia (GRID:grid.10939.32) (ISNI:0000 0001 0943 7661); Competence Centre on Health Technologies, Tartu, Estonia (GRID:grid.487355.8)
4 Cargill R&D Centre Europe BVBA, Vilvoorde, Belgium (GRID:grid.498107.3) (ISNI:0000 0004 0412 1766)
5 University of Tartu, Department of Oto-Rhino-Laryngology, Institute of Clinical Medicine, Tartu, Estonia (GRID:grid.10939.32) (ISNI:0000 0001 0943 7661)